Compare Mondaycom Ltd (MNDY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mondaycom Ltd vs TG Therapeutics Inc — how do they compare? Mondaycom Ltd trades at $72.51 (market cap $3.24B), while TG Therapeutics Inc trades at $54 (market cap $8.26B). The key difference: TG Therapeutics Inc is far larger — about 2.5× Mondaycom Ltd's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Mondaycom Ltd nearer its low. Which is the better fit depends on your goals.
| MNDY | TGTX | |
|---|---|---|
Market Cap | $3.24B | $8.26B |
Sector | Technology | Health |
52-Week High | $292.24 | $59.06 |
52-Week Low | $58.81 | $26.39 |
Enterprise Value | $2.21B | $8.50B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
